Capricor Therapeutics, Inc. (CAPR) vs Cerus Corporation (CERS)

A side-by-side comparison of Capricor Therapeutics, Inc. and Cerus Corporation across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — CAPR vs CERS

growth of $100 · dividends reinvested · last 10y
CAPR -75.8% (-13.2%/yr)CERS -62.6% (-9.4%/yr)CERS compounded faster over this window
050100Start $10020182020202220242026$24$37
CAPR CERS

CAPR vs CERS: by the numbers

  • •CERS is the larger company ($472M vs $447M market cap).
  • •Both run net losses; CAPR's is the smaller (0.00% vs -3.06% net margin).

Metrics side by side

Valuation

MetricCAPRCERS
P/S ratioN/A2.13
P/B ratio1.826.73
EV / EBITDA0.448036.17

Profitability

MetricCAPRCERS
Gross margin0.00%52.05%
Operating margin0.00%-0.73%
Net margin0.00%-3.06%
ROE-52.56%-9.69%
ROIC-40.25%-1.08%

Growth (annualized)

MetricCAPRCERS
Revenue CAGR (5Y)N/A15.74%
Total return CAGR (5Y)15.17%-17.30%

Frequently asked

How have CAPR and CERS total returns compared?
Over the past 10 years, CAPR delivered -13.84% and CERS delivered -9.37% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.